AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9554186 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous presentation of stimuli
Number of subjects: 0
Study 9554186 — intervention group
Group type: EXPERIMENTAL
Intervention: Career decided group
Number of subjects: 0
Study 9554186 — intervention group
Group type: EXPERIMENTAL
Intervention: Career undecided group
Number of subjects: 0
Study 7992149 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Toupet partial fundoplication
Number of subjects: 28
Study 7992149 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic Nissen fundoplication
Number of subjects: 28
Study 2660250 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol, 160 mg daily for 6 months (n = 15)
Number of subjects: 31
Study 2660250 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 16)
Number of subjects: 31
Study 31897524 — intervention group
Group type: EXPERIMENTAL
Intervention: semaglutide 1.0 mg once weekly
Number of subjects: 178
Study 31897524 — intervention group
Group type: EXPERIMENTAL
Intervention: canagliflozin 300 mg once daily
Number of subjects: 178
Study 30924902 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher incentives with both parent and child required to meet the goal
Number of subjects: 339
Study 30924902 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed payment structure
Number of subjects: 339
Study 30924902 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentivizing physical activity goals
Number of subjects: 339
Study 30924902 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentivizing dietary monitoring
Number of subjects: 339
Study 30924902 — intervention group
Group type: COMPARATOR
Intervention: Lottery for a large incentive
Number of subjects: 339
Study 28838145 — intervention group
Group type: EXPERIMENTAL
Intervention: Valganciclovir
Number of subjects: 26
Study 28838145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 26346836 — intervention group
Group type: EXPERIMENTAL
Intervention: Errorless Goal Management Training (EL-GMT)
Number of subjects: 67
Study 26346836 — intervention group
Group type: COMPARATOR
Intervention: Conventional Goal Management Training (GMT)
Number of subjects: 67
Study 23735647 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma vitamin D-binding protein (VDBP) levels
Number of subjects: 928
Study 23735647 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched controls)
Number of subjects: 928
Study 22132950 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat (approved doses)
Number of subjects: 2268
Study 22132950 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (commonly prescribed doses)
Number of subjects: 2268
Study 19638331 — intervention group
Group type: EXPERIMENTAL
Intervention: L2 spinal nerve block (n = 30), 1.5 mL of 1% lidocaine
Number of subjects: 60
Study 19638331 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous injection (control, n = 30), 1.5 mL of 1% lidocaine
Number of subjects: 60
Study 17129516 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tissue-type plasminogen activator (t-PA)
Number of subjects: 53
Study 15005346 — intervention group
Group type: EXPERIMENTAL
Intervention: MCNU-COP/MP
Number of subjects: 210
Study 15005346 — intervention group
Group type: COMPARATOR
Intervention: mCOP/MP
Number of subjects: 210
Study 11188774 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) treatment at a dose of 400 mg/kg bodyweight every 4 weeks
Number of subjects: 131
Study 11188774 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study 9277437 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of nutrients (protein, fat, carbohydrate) at 40, 90, and 160 kcal/h into the duodenum
Number of subjects: 26
Study 9277437 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of more calories into the duodenum
Number of subjects: 26
Study 9277437 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater amounts and concentrations of calories and carbohydrate during jejunoileal transit
Number of subjects: 26
Study 9277437 — intervention group
Group type: EXPERIMENTAL
Intervention: Delivery of bile acids and chymotrypsin to the distal jejunum
Number of subjects: 26
Study 8339523 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil 1000 mg/m2 and cis-platinum 20 mg/m2 for 5 consecutive days, with retinol palmitate at 15,000 IU b.i.d. in chemotherapy intervals
Number of subjects: 23
Study 3089050 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% plain (20 ml)
Number of subjects: 73
Study 3089050 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamorphine 2.5 mg in 10 ml normal saline
Number of subjects: 73
Study 3089050 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 73
Study 29122370 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded motor imagery (GMI) in addition to traditional rehabilitation for 8 weeks
Number of subjects: 36
Study 29122370 — intervention group
Group type: COMPARATOR
Intervention: Control group received traditional rehabilitation for 8 weeks
Number of subjects: 36
Study 24886638 — intervention group
Group type: EXPERIMENTAL
Intervention: Hatha yoga exercise program (8-week duration, group and home-based sessions)
Number of subjects: 36
Study 22270380 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss maintenance with dietary intervention for 6 months
Number of subjects: 125
Study 22270380 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled subjects (N=218)
Number of subjects: 125
Study 20604937 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation
Number of subjects: 203
Study 20604937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study 18354383 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril with hydrochlorothiazide
Number of subjects: 332
Study 18354383 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril with amlodipine
Number of subjects: 332
Study 18354383 — intervention group
Group type: COMPARATOR
Intervention: ACE inhibitor and calcium channel blocker
Number of subjects: 332
Study 18354383 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor and thiazide diuretic
Number of subjects: 332
Study 16061709 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathogen directed treatment (PDT)
Number of subjects: 262
Study 16061709 — intervention group
Group type: COMPARATOR
Intervention: Empirical broad spectrum antibiotic treatment (EAT)
Number of subjects: 262
Study 11919230 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy regimens including bolus fluorouracil (5‐FU), 5‐FU and leucovorin, 5‐FU and levamisole, and 5‐FU, leucovorin, and levamisole followed by chemoradiation therapy (pelvic irradiation at 45 Gy with a boost to 50.4 to 54 Gy)
Number of subjects: 1695
Study 10652116 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 6 mg (Imigran 0.5 mL)
Number of subjects: 10
Study 10652116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8888372 — intervention group
Group type: EXPERIMENTAL
Intervention: CDP-choline (single oral dose)
Number of subjects: 0
Study 1667392 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term intake of ispaghula (6 months)
Number of subjects: 0
Study 1667392 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat fibers (6 months)
Number of subjects: 0
Study 1667392 — intervention group
Group type: COMPARATOR
Intervention: Active phase of total colitis
Number of subjects: 0
Study 6289096 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral gangliosides (50 mg once a day) for 40 days
Number of subjects: 30
Study 6289096 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study 30719926 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-inclusive room layout
Number of subjects: 362
Study 30719926 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclusive room layout
Number of subjects: 362
Study 30719926 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive room layout
Number of subjects: 362
Study 28870140 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza vaccine (QIV)
Number of subjects: 3661
Study 28870140 — intervention group
Group type: COMPARATOR
Intervention: TIV-Victoria (Vic)
Number of subjects: 3661
Study 28870140 — intervention group
Group type: COMPARATOR
Intervention: TIV-Yamagata (Yam)
Number of subjects: 3661
Study 25602493 — intervention group
Group type: EXPERIMENTAL
Intervention: 35-min hazard perception training intervention
Number of subjects: 75
Study 25602493 — intervention group
Group type: COMPARATOR
Intervention: Placebo intervention
Number of subjects: 75
Study 22864680 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation under anaesthesia
Number of subjects: 64
Study 22864680 — intervention group
Group type: COMPARATOR
Intervention: Low load stretch (stretch)
Number of subjects: 64
Study 21678186 — intervention group
Group type: EXPERIMENTAL
Intervention: Campus bar context
Number of subjects: 383
Study 21678186 — intervention group
Group type: COMPARATOR
Intervention: Library context
Number of subjects: 383
Study 18987553 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostygmine (60 mg)
Number of subjects: 10
Study 18987553 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (20 mg)
Number of subjects: 10
Study 18987553 — intervention group
Group type: EXPERIMENTAL
Intervention: Bethanechol (25 mg)
Number of subjects: 10
Study 18987553 — intervention group
Group type: EXPERIMENTAL
Intervention: All three agents (Pyridostygmine, Buspirone, Bethanechol)
Number of subjects: 10
Study 16820420 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive multimedia internet‐based system (IMIS) + integrated psychostimulation program (IPP)
Number of subjects: 46
Study 16820420 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated psychostimulation program (IPP)
Number of subjects: 46
Study 16820420 — intervention group
Group type: COMPARATOR
Intervention: ChEI treatment
Number of subjects: 46
Study 12149529 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 2 x 500 microg
Number of subjects: 23
Study 12149529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 10102256 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 1 mg/day
Number of subjects: 1047
Study 10102256 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 5 mg/day
Number of subjects: 1047
Study 10102256 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 10 mg/day
Number of subjects: 1047
Study 10102256 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 15 mg/day
Number of subjects: 1047
Study 10102256 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 20 mg/day
Number of subjects: 1047
Study 10102256 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 30 mg/day
Number of subjects: 1047
Study 10102256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1047
Study 8589555 — intervention group
Group type: COMPARATOR
Intervention: Plasmatein (10%, v/v; 5 mg/ml)
Number of subjects: 7
Study 8589555 — intervention group
Group type: EXPERIMENTAL
Intervention: Lot 1 of SSS (HSA 84% and human globulins 16%)
Number of subjects: 7
Study 8589555 — intervention group
Group type: EXPERIMENTAL
Intervention: Lot 1 of SSS
Number of subjects: 7
Study 8589555 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipoprotein free SSS
Number of subjects: 7
Study 8589555 — intervention group
Group type: EXPERIMENTAL
Intervention: Lot 3 of SSS
Number of subjects: 7
Study 2317144 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training program (E) - three times weekly upper and lower conditioning program using target heart rates based on the symptom-limited exercise test (SLXT)
Number of subjects: 15
Study 2317144 — intervention group
Group type: COMPARATOR
Intervention: Control group (C) - continued daily nursing home routine
Number of subjects: 15
Study 347877 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromperidol (4 to 8 mg in one intake in the morning)
Number of subjects: 24
Study 347877 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (4 mg given twice a day)
Number of subjects: 24
Study 6122939 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 ml of 5% dextrose in water (D5W) and 1000 ml normal saline (7.5 g dextrose)
Number of subjects: 47
Study 6122939 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 ml of D5W, 350 ml of 5% dextrose in normal saline (D5NS), and 650 ml of normal saline (25 g dextrose)
Number of subjects: 47
Study 6122939 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 ml D5W and 1000 ml D5NS (57.5 g dextrose)
Number of subjects: 47
Study 6122939 — intervention group
Group type: EXPERIMENTAL
Intervention: 57.5 g of dextrose
Number of subjects: 47
Study 6122939 — intervention group
Group type: COMPARATOR
Intervention: 7.5 g dextrose
Number of subjects: 47
Study 31054219 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weeks of supervised exercise intervention
Number of subjects: 36
Study 31054219 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectus femoris CSA measurement
Number of subjects: 36
Study 29402228 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended nutritional intervention
Number of subjects: 148
Study 29402228 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 148
Study 27918630 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythmic auditory stimulation (RAS)
Number of subjects: 12
Study 27918630 — intervention group
Group type: COMPARATOR
Intervention: Conventional gait training (Control)
Number of subjects: 12
Study 24830759 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided vascular access
Number of subjects: 95
Study 24830759 — intervention group
Group type: COMPARATOR
Intervention: Landmark-guided vascular access
Number of subjects: 95
Study 22753637 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 274
Study 22753637 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement in depression
Number of subjects: 274
Study 22753637 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher socioeconomic status
Number of subjects: 274
Study 22753637 — intervention group
Group type: EXPERIMENTAL
Intervention: Fewer comorbid conditions
Number of subjects: 274
Study 20705512 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheohaemapheresis
Number of subjects: 0
Study 17681972 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal fluid administration (median 5050 ml, range 3563-8050 ml)
Number of subjects: 32
Study 17681972 — intervention group
Group type: COMPARATOR
Intervention: Restrictive fluid administration (median 1640 ml, range 935-2250 ml)
Number of subjects: 32
Study 17681972 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 32
Study 15533541 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity intervention group
Number of subjects: 2408
Study 15533541 — intervention group
Group type: COMPARATOR
Intervention: Low intensity intervention group
Number of subjects: 2408
Study 15533541 — intervention group
Group type: COMPARATOR
Intervention: Background population
Number of subjects: 2408
Study 11834770 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg folic acid
Number of subjects: 368
Study 11834770 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 microg folic acid
Number of subjects: 368
Study 11834770 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 368
Study 10078855 — intervention group
Group type: EXPERIMENTAL
Intervention: VLCD-strict
Number of subjects: 121
Study 10078855 — intervention group
Group type: COMPARATOR
Intervention: VLCD-plus
Number of subjects: 121
Study 10078855 — intervention group
Group type: COMPARATOR
Intervention: VLCD-mw
Number of subjects: 121
Study 7667959 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental diet with topinambur (mashed topinambur 100 g/day and cookies with topinambur 50 g/day for 4 weeks)
Number of subjects: 35
Study 7667959 — intervention group
Group type: COMPARATOR
Intervention: Control diet without topinambur
Number of subjects: 35
Study 2109195 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (200 micrograms four times daily for 12 weeks)
Number of subjects: 77
Study 2109195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 7402234 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive lay woman (doula)
Number of subjects: 136
Study 7402234 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 136
Study 30469103 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual feedback gait retraining
Number of subjects: 25
Study 30469103 — intervention group
Group type: COMPARATOR
Intervention: Control no-feedback group
Number of subjects: 25
Study 29576354 — intervention group
Group type: EXPERIMENTAL
Intervention: Aged garlic extract (AGE) 3.6 g daily for 6 weeks
Number of subjects: 51
Study 26871905 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate tocolysis
Number of subjects: 30
Study 26871905 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline
Number of subjects: 30
Study 25108611 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecological intervention program promoting healthy lifestyle behaviors
Number of subjects: 15
Study 25108611 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition domain strategies
Number of subjects: 15
Study 25108611 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity domain strategies
Number of subjects: 15
Study 25108611 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of Reciprocal Determinism as SCT construct
Number of subjects: 15
Study 23025957 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulator training (30-minute session)
Number of subjects: 24
Study 23025957 — intervention group
Group type: COMPARATOR
Intervention: Didactic lecture (30-minute session)
Number of subjects: 24
Study 19250838 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 298
Study 19250838 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 298
Study 19250838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 298
Study 17464919 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand sanitizer with 70% isopropyl alcohol and 0.5% chlorhexidine gluconate introduced in ward A
Number of subjects: 786
Study 17464919 — intervention group
Group type: COMPARATOR
Intervention: No intervention in ward B
Number of subjects: 786
Study 17464919 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand sanitizer in ward A
Number of subjects: 786
Study 15024318 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast Cancer Structured Clinical Instruction Module (BCSCIM)
Number of subjects: 48
Study 15024318 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study 12005118 — intervention group
Group type: COMPARATOR
Intervention: 0% SLS
Number of subjects: 12
Study 12005118 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% SLS
Number of subjects: 12
Study 12005118 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% SLS
Number of subjects: 12
Study 12005118 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.50% SLS
Number of subjects: 12
Study 12005118 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% SLS
Number of subjects: 12
Study 12005118 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical irritation scores on day 3
Number of subjects: 12
Study 12005118 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean perfusion
Number of subjects: 12
Study 9796236 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative shape features
Number of subjects: 0
Study 9796236 — intervention group
Group type: EXPERIMENTAL
Intervention: Connection angles (bias towards connection angles)
Number of subjects: 0
Study 9796236 — intervention group
Group type: EXPERIMENTAL
Intervention: Feature-based model of shape representation
Number of subjects: 0
Study 7611096 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiopeptin (750 micrograms/day)
Number of subjects: 112
Study 7611096 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiopeptin
Number of subjects: 112
Study 7611096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 1710742 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate (Bezalip Mono, 400 mg daily for 3 months)
Number of subjects: 24
Study 1710742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 361149 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine, 5 mg daily
Number of subjects: 40
Study 361149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31334927 — intervention group
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA (ABO), Hyaluronic Acid (HA) filler, and Restylane® Skinboosters (RSB)
Number of subjects: 0
Study 31334927 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic Acid (HA) filler alone
Number of subjects: 0
Study 31334927 — intervention group
Group type: COMPARATOR
Intervention: AbobotulinumtoxinA (ABO) alone
Number of subjects: 0
Study 26774526 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO (micellar casein without milk fat)
Number of subjects: 24
Study 26774526 — intervention group
Group type: COMPARATOR
Intervention: PRO + FAT (micellar casein with 26.7 g milk fat)
Number of subjects: 24
Study 26635308 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 ppm acrolein
Number of subjects: 18
Study 26635308 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 ppm acrolein
Number of subjects: 18
Study 26635308 — intervention group
Group type: COMPARATOR
Intervention: Clean air
Number of subjects: 18
Study 26635308 — intervention group
Group type: COMPARATOR
Intervention: 15 ppm ethyl acetate (EA)
Number of subjects: 18
Study 26635308 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 ppm acrolein with 15 ppm EA
Number of subjects: 18
Study 26635308 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 ppm acrolein with 15 ppm EA
Number of subjects: 18
Study 26635308 — intervention group
Group type: COMPARATOR
Intervention: Other exposure conditions (0.1 ppm acrolein with EA, 15 ppm EA)
Number of subjects: 18
Study 23433735 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based CBT-grounded interventions with e-diaries and personalized feedback
Number of subjects: 0
Study 21998095 — intervention group
Group type: EXPERIMENTAL
Intervention: Stiff and flexible prosthetic foot (CTA group)
Number of subjects: 17